BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen. BioLife is a publicly traded ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Life sciences company Repligen Corporation RGEN on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. BLFS for an enterprise value of approximately $1.5 billion. The ...
CEO Roderick de Greef highlighted strong quarterly performance, stating that "cell processing revenue increased 33% year-over-year, driving a 31% increase in total revenue for the quarter." He ...
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related ...
WALTHAM, Mass. and BOTHELL, Wash., July 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen,” or “the Company”), a life sciences company focused on bioprocessing technology ...
July 22 (Reuters) - Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider's presence in ...
Repligen gains access to cell-preservation products used in approved therapies BioLife valued at $31 per share, a 6.2% premium to last close Companies expect at least $20 million in first-year cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results